Drug intelligence / Profile preview

Colaren (Universidad de Guadalajara)

Development stage: Unknown
Lead developer: Universidad de Guadalajara
Administration: Oral

Overview

**Colaren** is a named dietary supplement product evaluated with annual intravenous zoledronic acid in a University of Guadalajara-sponsored Phase 3 study of secondary osteoporosis in HIV-positive and HIV-negative men. Public trial materials identify Colaren as a supplement but do not disclose its active ingredient composition, dosage form, manufacturer, or a defined molecular mechanism. It should therefore not be conflated with zoledronic acid, calcium, vitamin D, or any specific collagen product.

Brand names: Colaren

Beyond the preview

Go deeper on Colaren (Universidad de Guadalajara).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colaren (Universidad de Guadalajara).

Explore the full profile